Functional role of PPAR-\(\gamma\) on the proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis

Xiao-Feng Li\(^1, 2, 3\), Ying-Yin Sun\(^1, 2, 3\), Jing Bao\(^1, 2, 3, 4\), Xin Chen\(^1, 2, 3\), Yu-Huan Li\(^1, 2, 3\), Yang Yang\(^1, 2, 3\), Lei Zhang\(^1, 2, 3\), Cheng Huang\(^1, 2, 3\), Bao-Ming Wu\(^1, 2, 3\), Xiao-Ming Meng\(^1, 2, 3\) & Jun Li\(^1, 2, 3\)

Peroxisome proliferator-activated receptor (PPAR)-\(\gamma\) is involved in both normal physiological processes and pathology of various diseases. The purpose of this study was to explore the function and underlying mechanisms of PPAR-\(\gamma\) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) proliferation and migration. In the present study, we found PPAR-\(\gamma\) expression was remarkably reduced in RA synovium patient compare with OA and normal, as well as it was low-expression in Adjuvant-induced arthritis (AA). Moreover, inhibition PPAR-\(\gamma\) expression by T0070907 (12.5 \(\mu\)M) or PPAR-\(\gamma\) siRNA could promote FLSs proliferation and expressions of c-Myc, Cyclin D1, MMP-1, and MMP-9 in AA FLSs, except for TIPM-1. These data indicate that up-regulation of PPAR-\(\gamma\) may play a critical role in RA FLSs. Interestingly, co-incubation FLSs with Pioplitazone (25 \(\mu\)M) and over expression vector with pEGFP-N1-PPAR-\(\gamma\) reduced proliferation and expressions of c-Myc, Cyclin D1, MMP-1, and MMP-9 in AA FLSs besides TIMP-1. Further study indicates that PPAR-\(\gamma\) may induce activation Wnt/\(\beta\)-catenin signaling. In short, these results indicate that PPAR-\(\gamma\) may play a pivotal role during FLSs activation and activation of Wnt/\(\beta\)-catenin signaling pathway.

Rheumatoid arthritis (RA) is characterized by tumor-like expansion of the synovium and the subsequent destruction of adjacent articular cartilage and bone\(^1\). At the same time, angiogenesis is required to maintain the chronic inflammatory state by transporting inflammatory cells to the site of synovitis and supplying nutrients to the pannus\(^2\). In RA synovium, migration and invasion of activated fibroblast-like synoviocytes (FLSs), the major cell population in invasive pannus, actively participate in the inflammatory processes of RA\(^3, 4\), such as produce pro-inflammatory cytokines TNF-\(\alpha\), IL-6\(^5, 6\), matrix metalloproteinases and angiogenic factors\(^7\). One of the RA features is the excessive proliferation, migration and activation of FLSs and formation of pannus that invades adjacent cartilage and bone\(^8\). So inhibition of FLSs proliferation and migration is an ideal target for the treatment of RA. Many research studies\(^9, 10\) have been carried out the expression of c-Myc, Cyclin D1, MMP-3, MMP-9 and TIMP-1 are proved to be related with cell proliferation and migration. Although the exact causes of RA remain unknown, FLSs proliferation, migration and immunological dysregulation by inflammatory cytokines\(^1\) has been shown to be involved in driving the inflammation and synovial cell proliferation that result in joint destruction in RA patients. However, little is currently known on the molecular mechanisms underlying proliferation, migration and invasion of activated FLS.

The latest achievement obviously suggested that peroxisome proliferator-activated receptor (PPAR)-\(\gamma\) might contribute to the persistent expression of pro-inflammatory cytokines in RA\(^11, 12\). The PPAR-\(\gamma\) belongs to the PPAR family of nuclear hormone receptors best known for their role in regulating various genes involved in glucose homeostasis, lipid metabolism, and adipocyte differentiation\(^13, 14\). Pioplitazone, a thiazolidinedione class synthetic PPAR-\(\gamma\) agonist, is used for treatment of patients with type II diabetes mellitus\(^15\). More importantly, PPAR-\(\gamma\) has been known to have remarkably anti-inflammatory activities and anti-proliferation\(^16, 17\). In a recent
study have performed that PPAR-γ was significantly associated with RA\textsuperscript{11,17,18}. However, it remains unknown the expresses of PPAR-γ and what is the pathophysologic role of FLSs proliferation in RA.

An increasing body of evidence has indicated that Wnt/β-catenin pathway, one might rationalize that untimely activation of Wnt/β-catenin pathway is partly responsible for driving RA FLS activation and RA pathogenesis\textsuperscript{19,20}. The Wnt/β-catenin pathway is a conserved signal transduction pathway that regulates a variety of biological processes, including signal transduction, cell cycle, cell proliferation, migration, differentiation, apoptosis, cell adhesion and tumorigenesis, and play a important role in limb development and joint formation\textsuperscript{19,21,22}. In the absence of Wnt ligand, the signaling pathways in the resting state, β-catenin level is widely used as a sentinel marker Wnt/β-catenin pathway under pathological conditions\textsuperscript{23,24}. To further elucidate the relationship between PPAR-γ and FLSs activation in RA, in particularly, we found that the increased expression of PPAR-γ contributed to proliferation and migration of FLSs and was closely associated with Wnt/β-catenin pathway activation in RA pathogenesis.

**Results**

**The expression of PPAR-γ was down-regulated in RA FLSs.** To affirm the role of PPAR-γ in RA, model of AA was established by injection with the complete Freund's adjuvant. Histopathological analysis (Fig. 1a) confirmed the model of AA was established successfully, increased remarkable inflammatory cells infiltrations. We performed immunohistochemical and western blot analysis the expression of PPAR-γ was down-regulated observably in RA FLSs compare with normal, as show Fig. 1b,c and d. The expression of Vimentin studies (Fig. 1e) indicated that the cells were derived from synovial tissues was FLSs. Similarly, western blot and Q-PCR analysis showed PPAR-γ mRNA and protein levels (Fig. 1f,g) were down-regulated significantly in FLSs isolated from AA rats' synovium. Moreover, we also have measured PPAR-γ protein expression by immunofluorescence staining (Fig. 1e) in AA FLSs was lower than normal FLSs. Thus, these results suggesting that the expression of PPAR-γ was observably reduced in RA FLSs.

**Effect of PPAR-γ inhibitor increases FLSs proliferation and migration.** To identify the significance of PPAR-γ in the RA FLSs, we have measured the effect of PPAR-γ on the proliferation and migration FLSs by treated with PPAR-γ inhibitor T0070907 in AA and normal rats. First, we investigated the effect of T0070907 on the expression of PPAR-γ (Fig. 2a), addition of 12.5 μM suppressed obviously the expression of PPAR-γ mRNA with Q-PCR assays in normal FLSs as show Fig. 2b and c. The results of western blot and Q-PCR showed the expression of PPAR-γ was down-regulated markedly in varying degrees with 12.5 μM T0070907 in normal and AA FLSs as show Fig. 2b and c. More significantly, western blot and Q-PCR has verified expression of protooncogene c-Myc and cyclin protein Cyclin D1 were up-regulated markedly by PPAR-γ inhibitor 12.5 μM T0070907 in normal and AA FLSs (Fig. 2b and c). In addition, MMP-3 and MMP-9 mRNA and protein expression also were up-regulated observably by T0070907 in normal and AA FLSs, whereas TIPM-1 was down-regulated (Fig. 2d and e). Similarly, cell cycle analysis (Fig. 2f) also suggested that treatment of FLSs with T0070907 resulted in increased varying degrees in S phase and G2/M phase. Remarkably, evidences were collected by CFDA SE cell proliferation assay and BrdU cell proliferation ELISA, as show Fig. 2b and c, that the normal and AA FLSs were promoted observably proliferation with T0070907. What's more, wound-healing assay and cell invasion assay have proved that the normal and AA FLSs were promoted observably migration with T0070907 (Fig. 2i and j). Thus, these researches had proved that effect of PPAR-γ inhibitor T0070907 increased markedly FLSs proliferation and migration in normal and AA rats.

**Effect of PPAR-γ siRNA increases FLSs proliferation and migration.** In order to provide additional evidence that PPAR-γ is involved in the proliferation and migration of RA FLSs, siRNA specific for rat PPAR-γ was used to knockdown gene expression in AA FLSs. Normal and AA FLSs treated with control siRNA or PPAR-γ siRNA was exposed to 48 h following the transfection with 100 nM PPAR-γ siRNA, the level of PPAR-γ mRNA and protein were reduced remarkably compared with the cells transfected with control siRNA (Fig. 3a). As same as expected, the expression of c-Myc and Cyclin D1 mRNA and protein were up-regulated by PPAR-γ siRNA in normal and AA FLSs as show Fig. 3a and b. Furthermore, MMP-3 and MMP-9 mRNA and protein expression also were up-regulated observably by PPAR-γ siRNA, however, TIPM-1 was down-regulated markedly in normal and AA FLSs as show Fig. 3c and d. Similarly, cell cycle analysis also suggested that treatment of FLSs with PPAR-γ siRNA resulted in increased varying degrees in S phase and G2/M phase in normal and AA rats (Fig. 3e). Remarkably, evidence was collected by CFDA SE cell proliferation assay and BrdU cell proliferation ELISA, as show Fig. 3f and g, that the normal and AA FLSs were promoted observably proliferation with PPAR-γ siRNA. What's more, wound-healing assay and cell invasion assay have proved that the normal and AA FLSs were promoted observably migration with PPAR-γ siRNA (Fig. 3i and j). Taken together, our findings suggested that inhibited PPAR-γ expression could increase FLSs proliferation and migration in normal and AA rats and PPAR-γ may contribute to the progression of RA.

**Effect of PPAR-γ agonist inhibits FLSs proliferation and migration.** This is so clear that inhibited PPAR-γ expression could increase FLSs proliferation and migration in normal and AA rats. Based on the above research, we proposed over-expression of PPAR-γ may inhibit FLSs proliferation and migration. To further determine the underlying mechanism of PPAR-γ during FLSs proliferation and migration, PPAR-γ agonist Pioditazone hydrochloride was used to over-expression of PPAR-γ. Q-PCR assays showed 25 μM Pioditazone could increase obviously the expression of PPAR-γ mRNA in AA FLSs (Fig. 4a). In addition, with 25 μM Pioditazone in FLSs, the expression of PPAR-γ was up-regulated significantly in normal and AA FLSs (Fig. 4b and c). Conversely, after treating with 25 μM Pioditazone, expressions of c-Myc and Cyclin D1 mRNA and protein were down-regulated remarkably in normal and AA FLSs, as show Fig. 4b and c. Meanwhile, MMP-3 and MMP-9 mRNA and
Figure 1. The expression of PPAR-γ was down-regulated in RA FLSs. (a) Representative H&E staining of AA and normal synovial tissues in rat (original magnification, ×10). (b) Representative H&E staining of RA, OA and normal synovial tissues in human (original magnification, ×10). (c) The expression of PPAR-γ in RA, OA and normal synovial tissue was analyzed by IHC staining analysis in human. (d) The protein level of PPAR-γ was analyzed by Western blot in RA, OA and normal synovial tissue. (e) The expression of PPAR-γ and Vimentin were analyzed by double immunofluorescence staining analysis in rat AA and normal FLSs. (f) The protein level of PPAR-γ was analyzed by Western blot in AA and normal FLSs. (g) The mRNA level of PPAR-γ was analyzed by Q-PCR in AA and normal FLSs. All values were expressed as mean ± SEM. **P < 0.01 vs normal group.
Figure 2. Effect of PPAR-γ inhibitor increases FLSs proliferation and migration. (a) Concentration-dependent inhibition expression of PPAR-γ mRNA by T0070907 in normal FLSs, tested by Q-PCR assays. (b) The mRNA levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Q-PCR in FLSs with T0070907 (12.5 μM). (c) The protein levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Western blot in FLSs with T0070907 (12.5 μM). (d) The mRNA levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Q-PCR in FLSs with T0070907 (12.5 μM). (e) The protein levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Western blot in FLSs with T0070907 (12.5 μM). (f) Cell cycle of FLSs were incubated with T0070907 (12.5 μM) for 48 h and then subjected to the FACS analysis. (g) After stained with CFDA-SE, FLSs were incubated with T0070907 (12.5 μM) for six days and then subjected to the FACS analysis. (h) BrdU proliferation assay were treated with T0070907 (12.5 μM) 48 h in FLSs. (i) FLSs were treated with T0070907 (12.5 μM), and migration into the wound-healing 24 h was photographed (original magnification, ×10). (j) FLSs were treated with T0070907 (12.5 μM), and transwell migration 48 h was photographed (original magnification, ×10). All values were expressed as mean ± SEM. *P < 0.05, **P < 0.01 vs normal group. *P < 0.05, **P < 0.01 vs model group.
Figure 3. Effect of PPAR-γ siRNA silencing increases FLSs proliferation and migration. (a) The mRNA levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Q-PCR in FLSs with PPAR-γ siRNA. (b) The protein levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Western blot in FLSs with PPAR-γ siRNA. (c) The mRNA levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Q-PCR in FLSs with PPAR-γ siRNA. (d) The protein levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Western blot in FLSs with PPAR-γ siRNA. (e) Cell cycle of FLSs were incubated with PPAR-γ siRNA for 48 h and then subjected to the FACS analysis. (f) After stained with CFDA-SE, FLSs were incubated with PPAR-γ siRNA for six days and then subjected to the FACS analysis. (g) BrdU proliferation assay were treated with PPAR-γ siRNA 48 h in FLSs. (h) FLSs were treated with PPAR-γ siRNA, and migration into the wound-healing 24 h was photographed (original magnification, ×10). (i) FLSs were treated with PPAR-γ siRNA, and transwell migration 48 h was photographed (original magnification, ×10). All values were expressed as mean ± SEM. *P < 0.05, **P < 0.01 vs normal group. *P < 0.05, **P < 0.01 vs model group.
Figure 4. Effect of PPAR-γ agonist inhibits FLSs proliferation and migration. (a) Concentration-dependent inhibition expression of PPAR-γ mRNA by Pioditazone in AA FLSs, tested by Q-PCR assays. (b) The mRNA levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Q-PCR in FLSs with Pioditazone. (c) The protein levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Western blot in FLSs with Pioditazone. (d) The mRNA levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Q-PCR in FLSs with Pioditazone. (e) The protein levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Western blot in FLSs with Pioditazone. (f) Cell cycle of FLSs were incubated with Pioditazone for 48 h and then subjected to the FACS analysis. (g) After stained with CFDA-SE, FLSs were incubated with Pioditazone for six days and then subjected to the FACS analysis. (h) BrdU proliferation assay were treated with Pioditazone 48 h in FLSs. (i) FLSs were treated with Pioditazone, and migration into the wound-healing 24 h was photographed (original magnification, ×10). (j) FLSs were treated with Pioditazone, and transwell migration 48 h was photographed (original magnification, ×10). All values were expressed as mean ± SEM. *P < 0.05, **P < 0.01 vs normal group. *P < 0.05, **P < 0.01 vs model group.
protein expression (Fig. 4d and e) also were down-regulated observably by Pioditazone, whereas TIPM-1 were up-regulated markedly in normal and AA FLSs. Consistent with the cell proliferation results, as same as expected flow cytometry analysis showed down-expression of PPAR-γ by 25 μM Pioditazone for 48 h in decreased in S phase and G2/M phase significantly in normal and AA rats, as show Fig. 4f. Remarkably, evidence was collected by CFDA SE cell proliferation assay and BrdU cell proliferation ELISA (Fig. 4g and h) that the normal and AA FLSs were suppressed observably proliferation with Pioditazone. What's more, wound-healing assay and cell invasion assay have proved that the normal and AA FLSs were suppressed observably proliferation with Pioditazone, as show Fig. 4i and j. These results suggested that treatment of FLSs with Pio 25 μΜ had a profound inhibitory effect on proliferation and migration of FLSs.

**Effect of over expression vector of PPAR-γ inhibits FLSs proliferation and migration.** In order to provide additional evidence that PPAR-γ is involved in the proliferation and migration of RA FLSs, over expression vector with pEGFP-N1-PPAR-γ for rat was used to over expression of PPAR-γ in AA FLSs. Western blot and Q-PCR (Fig. 5a and b) showed the expression of PPAR-γ was up-regulated observably with pEGFP-N1-PPAR-γ in normal and AA FLSs. In addition, after treating with pEGFP-N1-PPAR-γ, expressions of c-Myc and Cyclin D1 mRNA and protein were down-regulated remarkably in normal and AA FLSs (Fig. 5a and b). Meanwhile, MMP-3 and MMP-9 mRNA and protein expression also were down-regulated observably by pEGFP-N1-PPAR-γ, conversely, TIPM-1 were up-regulated markedly, as show Fig. 5c and d. As same as Pioditazone, over-expression of PPAR-γ by pEGFP-N1-PPAR-γ resulted in decreased in S phase and G2/M phase significantly by flow cytometry analysis in normal and AA rats (Fig. 5c). Consistent with the cell proliferation results, CFDA SE cell proliferation assay and BrdU cell proliferation ELISA (Fig. 5f and g) has proved that the normal and AA FLSs were suppressed observably proliferation with pEGFP-N1-PPAR-γ. What's more, wound-healing assay and cell invasion assay have proved that the normal and AA FLSs were suppressed observably proliferation with pEGFP-N1-PPAR-γ (Fig. 5b and i). These evidences proved that treatment of FLSs with pEGFP-N1-PPAR-γ had a profound inhibitory effect on proliferation and migration of FLSs. It may be involved in the proliferation of FLSs, and play a pivotal role in the pathogenesis of RA.

**PPAR-γ may modulate FLSs proliferation and migration and be closely associated with Wnt/β-catenin signaling pathway.** It has proved Wnt/β-catenin signaling plays a fundamental role in cell differentiation and proliferation. To investigate the effect of PPAR-γ on Wnt/β-catenin signaling in FLSs proliferation and migration, we firstly examined the expression profiles of β-catenin, a major component of Wnt/β-catenin pathway. Western blot analysis performed that β-catenin was up-regulated obviously in AA FLSs compared with normal. Moreover, inhibition PPAR-γ by T0070907 (12.5 μΜ) or PPAR-γ siRNA (Fig. 6a and b), β-catenin expression was enhanced significantly in normal and AA FLSs. In particular, Pioditazone (25 μΜ) or pEGFP-N1-PPAR-γ (Fig. 6c and d) supressed Wnt/β-catenin signaling, the expression of β-catenin was decreased substantially in normal and AA FLSs. In addition, Fig. 6e showed that after treating with PPAR-γ siRNA and XAV-939, expressions of c-Myc, Cyclin D1, MMP-3 and MMP-9 proteins were down-regulated remarkably, however, they were unchanged between with XAV-939 in AA FLSs. Taken together, all the above results indicated that PPAR-γ could modulate FLSs proliferation and migration and be closely associated with Wnt/β-catenin signaling pathway.

**Discussion**

The results of this study show that: 1) the expression of PPAR-γ was down-regulated substantially in RA FLSs; 2) PPAR-γ inhibitor T0070907 or PPAR-γ siRNA could increase observably FLSs proliferation and migration in normal and AA; 3) PPAR-γ agonist Pioditazone or pEGFP-N1-PPAR-γ could suppress substantially FLSs proliferation and migration in normal and AA; 4) PPAR-γ could modulate FLSs proliferation and migration and be closely associated with Wnt/β-catenin signaling pathway.

Adjuvant arthritis (AA) is a model of experimental RA that is induced by injection complete Freund’s adjuvant (CFA)25,26. The AA in rats has similar characteristics to RA in aspects of histology and immunology and is a useful test system for evaluating therapies for RA. Therefore, we chose AA rats to affirm the role of PPAR-γ rather than RA. Recent progress in research has substantiated FLSs are key effector cells in inflammatory arthritic diseases16,17. In addition, the hyperplastic FLSs population potentially promotes lymphocyte and macrophage infiltration34, recruitment and retention by produces cytokines35, chemokines36, extracellular matrix proteins37 and cell adhesion molecules37. Migration and invasion of activated FLSs into cartilage and bone are critical events during invasive pannus formation in RA synovium14. However, there are no approved drugs that are known to target the FLSs in RA, and the underlying mechanisms driving FLSs activation remain unresolved. Hence, targeted suppress proliferation and migration of FLSs may potentially complement the current therapeutics without major deleterious effects on adaptive immune responses.

PPAR-γ is the most ample PPAR subtype in white adipose tissue, and its main function is administer of insulin sensitivity, fatty acid uptake and glucose homeoaeasisis2,3. First, in this paper, we agree with Marder W and his colleagues14 that PPAR-γ is observably reduced by immunohistochemical and western blot in RA and AA FLSs compare with normal. Moreover, we also have measured PPAR-γ expression by immunofluorescence staining in AA FLSs was lower than normal. What’s more, inhibition of PPAR-γ expression with T0070907 12.5 μM or PPAR-γ siRNA could active protooncogene c-Myc, cyclin protein Cyclin D1, matrix metalloproteinases (MMPs) proteins MMP-3 and MMP-9 over-expression, whereas TIPM-1 was down-regulated. It is known that Cyclin D1 and c-Myc are common downstream molecules of this pathway, which are proved to be related with cell proliferation15. In addition, numerous experimental and clinical studies indicating the expression of MMP-3 and MMP-9 a family of zinc-dependent endopeptidases, provide condition for the cell migration and invasion14.
Figure 5. Effect of over expression vector of PPAR-γ inhibits FLSs proliferation and migration. (a) The mRNA levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Q-PCR in FLSs with pEGFP-N1-PPAR-γ. (b) The protein levels of PPAR-γ, c-Myc and Cyclin D1 were analyzed by Western blot in FLSs with pEGFP-N1-PPAR-γ. (c) The mRNA levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Q-PCR in FLSs with pEGFP-N1-PPAR-γ. (d) The protein levels of MMP-3, MMP-9 and TIMP-1 were analyzed by Western blot in FLSs with pEGFP-N1-PPAR-γ. (e) Cell cycle of FLSs were incubated with pEGFP-N1-PPAR-γ for 48 h and then subjected to the FACS analysis. (f) After stained with CFDA-SE, FLSs were incubated with pEGFP-N1-PPAR-γ for six days and then subjected to the FACS analysis. (g) BrdU proliferation assay were treated with pEGFP-N1-PPAR-γ 48 h in FLSs. (h) FLSs were treated with pEGFP-N1-PPAR-γ and migration into the wound-healing 24 h was photographed (original magnification, ×10). (i) FLSs were treated with pEGFP-N1-PPAR-γ, and transwell migration 48 h was photographed (original magnification, ×10). All values were expressed as mean ± SEM. #P < 0.05, ##P < 0.01 vs normal group. *P < 0.05, **P < 0.01 vs model group.
Figure 6. PPAR-γ may modulate FLSs proliferation and be closely associated with Wnt/β-catenin signaling pathway. (a) The protein level of β-catenin was analyzed by Western blot in FLSs with T0070907 (12.5 μM). (b) The protein level of β-catenin was analyzed by Western blot in FLSs with PPAR-γ siRNA. (c) The protein level of β-catenin was analyzed by Western blot in FLSs with Pioglitazone (25 μM). (d) The protein level of β-catenin was analyzed by Western blot in FLSs with over expression vector pEGFP-N1-PPAR-γ. (e) The protein level of c-Myc, Cyclin D1, MMP-3, MMP-9 and β-catenin was analyzed by Western blot in AA FLSs. All values were expressed as mean ± SEM. *P < 0.05, **P < 0.01 vs normal group. *P < 0.05, **P < 0.01 vs model group. (e) *P < 0.05, **P < 0.01 vs model group; ***P < 0.01 vs PPAR-γ siRNA group; &P < 0.05, &&P < 0.01 vs model group.
the other hand, the action of all of MMPs is regulated by a group of endogenous tissue inhibitors of metalloproteinases (TIMPs). More significantly, cell cycle analysis and CFDA SE cell proliferation assay, BrdU cell proliferation ELISA, wound-healing assay and cell invasion assay also suggested that inhibition of PPAR-γ expression increased markedly FLSs proliferation and migration in normal and AA rats.

It is necessary to consider whether over-expression of PPAR-γ could improve or regulate FLSs proliferation and migration. Indeed, PPAR-γ has been regarded as the receptor of the thiazolidinedione, a resultant chemi-

cal among anti-diabetic drugs, and in consequence, it could be targeted by many drug candidates. Although not explicitly demonstrated, it is very likely that the side effects result from high doses of full agonists, such as Pioglitazone, Bezafibrate and metaglidasen. As a result, with treatment of FLSs with Pioglitazone 25μM or over expression vector with pEGFP-N1-PPAR-γ had a profound inhibitory effect on proliferation and migration of FLSs in normal and AA rats. More importantly, PPAR-γ has been known to have remarkably anti-inflammatory activities. In this study, our results showed that over-expression PPAR-γ could down-regulation expression of c-Myc, Cyclin D1, MMP-3 and MMP-9, and up-regulation expression of TIPM-1. To summarize, over-expression of PPAR-γ expression reduced significantly proliferation and migration of FLSs in AA. Regarding this last comment, of course, we suppose that PPAR-γ inhibits FLSs proliferation and migration through reduction insulin resistance and lipid metabolism, and further studies are required to comprehensively explore the role of PPAR-γ in RA.

This is so clear that activation of Wnt signaling disrupts this destruction complex, which leads to accumulation of β-catenin in the cytoplasm and finally translocation to nucleus. Our results also demonstrate this viewpoint that inhibition PPAR-γ by T0070907 12.5μM or PPAR-γ siRNA, β-catenin expression was enhanced significantly in normal and AA FLSs. In particular, Pioglitazone 25μM or pEGFP-N1-PPAR-γ suppressed Wnt/β-catenin signaling, the expression of β-catenin was substantially decreased in normal and AA FLSs. Take together, these dates suggested that PPAR-γ mediated FLSs activation, proliferation and migration and was closely associated with activation of Wnt/β-catenin signaling pathway in RA.

In summary, our findings in the present study suggested that PPAR-γ might play a pivotal role during FLSs activation and be closely associated with activation of Wnt/β-catenin signaling pathway. It is one more competent and qualified opinion that the over-expression of PPAR-γ suppresses AA FLSs proliferation and migration, indicating the potential of PPAR-γ as a therapeutic target for RA. Further research is needed to clarify if PPAR-γ could be used as a diagnostic marker and prognostic indicators of RA.

Materials and Methods

Human synovial tissue collection. Synovial tissue was obtained from patients with RA (n = 5) and osteoarthritis (OA, n = 15) according to the American College of Rheumatology 1987 revised criteria during joint synovectomies and 4 trauma patients with no history of acute or chronic arthritis served as controls. All patients signed informed consent to take part in the study. The study protocol was approved by the ethics boards of Anhui Medical University, and tissue specimen acquisition was performed in accordance with the institutional guidelines. The written informed consent was obtained from all subjects.

Materials and reagents. T0070907 and Cell Proliferation ELISA, BrdU(colorimetric) were purchased from Sigma Inc. (St. Louis, MO, USA). Pioglitazone hydrochloride (HPLC ≥ 98%) was purchased from Dalian Meilun Biotech Co., Ltd (Dalian, China). Rabbit anti-PPAR-γ, anti-β-catenin, anti-c-Myc and rabbit anti-Cyclin D1 monoclonal antibody were purchased from Cell Signaling (Danvers, MA, USA) and Rabbit anti-β-actin monoclonal antibody was purchased from Bioworld (Shanghai, China). Secondary antibody for goat anti-rabbit immunoglobulin (IgG) horse radish peroxidase (HRP) was purchased from Beijing Zhongshan Biotechnology Corporation (Beijing, China). PPAR-γ and β-actin primers were produced from Shanghai Sangon Biological and Technological Company (Shanghai, China).

RA rat model. Adult female Sprague-Dawley (SD) rats (160–200g) were treatment with complete Freund’s adjuvant (Sigma Inc., MO, USA) for 24 days 0.1 ml per 100 g body weight by paw injection at the left paw to induce RA rat models. Normal control rats were injected in paw with 0.1 ml of normal saline per 100 g body weight at same time. All the animal experiments were performed in accordance with the Regulations of the Experimental Animal Administration issued by the State Committee of Science and Technology of China. Efforts were made to minimize the number of animals used and their suffering. Animals were maintained in accordance with the Guides of Center for Developmental Biology, Anhui Medical University for the Care and Use of Laboratory. Animals and all experiments used protocols approved by the institutions’ subcommittees on animal care.

Histopathology. The synovium specimens were fixed with 4% paraformaldehyde for 24 h and embedded in paraffin. Hematoxylin and eosin (H&E) staining and immunohistochemistry were performed according to a standard procedure. The pathological changes were assessed and photographed under an Olympus BX-51 microscope.

Cell culture. FLSs were derived from the synovial tissues of AA and control rats. The cells were cultured in cell culture flasks in high-glucose DMEM medium (Hyclone, USA) supplemented with 20% (v/v) heat-inactivated fetal bovine serum (FBS) (Millipore, USA), 100 U/ml of penicillin, and 100 mg/ml of streptomycin (both from Beyotime, China). Cell cultures were maintained at 37 °C at an atmosphere of 5% CO₂.

Immunofluorescence staining. Cultured FLSs were plated in DMEM supplemented with 20% FBS at a density of 1–2 × 10⁵ cells/ml. Immunofluorescence staining was performed with Rabbit anti-PPAR-γ and...
anti-Vimentin (Alexa Fluor 594 Conjugated) (both from Cell Signaling, USA). Alexa Fluor 488-Conjugated AffiniPure Goat anti-rabbit IgG (H + L) (Beijing Zhongshan Biotechnology Corporation, China) was used as secondary antibody. Counterstaining of nuclei was performed with 4′,6-diamidino-2-phenylindole (DAPI; Beyotime, China).

**Small interfering RNA silencing.** FLSs were transfected with 100 nM of small interfering RNA (siRNA) and pEGFP-N1-PPAR-γ using Lipofectamine 2000 (Invitrogen, CA, USA) according to the manufacturer’s instructions. The oligonucleotide sequences were as follows: PPAR-γ-siRNA (rat), 5′-CCUCCCGUGAUAAUAAGATT-3′ for the sense strand and 5′-UCUUUAUUC AUCAGGGAGTT-3′ for the antisense strand. A negative scrambled siRNA (GenePharma, Shanghai, China) was used in parallel. Cells were cultured at 37 °C for 6 h, and then, Q-PCR, Western blot, and flow cytometer (FCM) were used 48 h after siRNA transfection.

**Plasmid construction.** Expression plasmid for PPAR-γ was generated by amplifying complementary DNA (cDNA) from pancreas cDNA and inserting cDNA coding for PPAR-γ into destination vectors by Gateway cloning (Invitrogen, USA). The N-terminal region of the PPAR-γ coding region containing the predicted CARD domain was cloned into pEGFP-N1 vector by using restriction sites SalI and AgeI. Cells transfection was performed with the Lipofectamine™ 2000 according to the manufacturer’s manuals.

**Cell cycle analysis.** To analyze the intracellular DNA content, FLSs were fixed in 70% ethanol at 4 °C overnight after 48 h treatment with T0070907, PPAR-γ-siRNA and Pioditazone, pEGFP-N1-PPAR-γ. FLSs were centrifuged at 1000 g for 5 min and re-suspended in PBS. After then, cells were stained with 0.5 ml of propidium iodide (PI) staining buffer (Beyotime, China), which contains 200 mg/ml RNase A, 50 μg/ml PI, at room temperature for 30 min in the dark. Flow cytometric analysis (FACS) was performed on Beckman Coulter.

**BrdU proliferation assay.** FLSs (1000 cells/well) were seeded in 96-well plates with DMEM and 20% FBS and cultured 2 days. And then, Cells were exposed to T0070907, PPAR-γ-siRNA and Pioditazone, pEGFP-N1-PPAR-γ for 48 h. The cells were labeled with 20 ml/well of BrdU labeling solution as described previously, and then incubated with 200 ml/well of FixDenat. After incubated with 100 ml/well of Anti-BrdU-POD working solution for 90 min and washed 3 times, substrate solution (TMB) was added and the absorbance of each well was read at 370 nm with an ELISA plate reader (Biotek, USA).

**Wound-healing.** FLSs were with DMEM and 20% FBS and cultured 2 days in 24-well plate (5 × 10^5/ml cells/well). Then, cells were serum deprived and scratched, treated with T0070907, PPAR-γ-siRNA and Pioditazone, pEGFP-N1-PPAR-γ. 24 h later Type II alveolar epithelial cells were fixed with methanol, stained with crystal violet stain, and viewed under an Olympus BX-51 microscope.

**Transwell experiments.** For the migration assays, after with T0070907, PPAR-γ-siRNA and Pioditazone, pEGFP-N1-PPAR-γ, 1 × 10^6 cells in 1% FBS media were placed into the upper chamber of an insert (8-μm pore size; Millipore, USA). And medium containing 20% FBS was added to the lower chamber. After incubation for 48 h, Cells that had migrated or invaded through the membrane were stained with methanol and 0.1% crystal violet stain, and viewed under an Olympus BX-51 microscope.

**Quantitative real-time PCR (Q-PCR).** Total RNA was extracted from cultured FLS by using TRizol (Invitrogen, USA) according to the manufacturer’s protocol, and reverse transcribed to cDNA using Takara kit (Japanese). The reaction mixture was prepared according to the manufacture’s instruction using SYBR Green q-PCR Master Mix (Vazyme Biotech, Nanjing, China). The mRNA expression of PPAR-γ and β-actin were detected by the quantitative real-time PCR (q-PCR). The primers used were listed as following: PPAR-γ (forward: 5′-CAGCGGTAGGGATGAAATAGTGA-3′; reverse: 5′-TGCTCTCCGTCCTATGTTGCG-3′), c-Myc (forward: 5′-TGCTCTCCGTCTAATGTTGGC-3′; reverse: 5′-CAGTCCTCGATGATGTGTTTCTGTA-3′), Cyclin D1 (forward: 5′-CAGCGGTGGAAGTGAATAGTGCA-3′; reverse: 5′-GGAATGTTTTGAGAACATGGAGA-3′), MMP-3 (forward: 5′-ATGATGACACGAGTCAGAGTCA-3′; reverse: 5′-CCATGGCGTATAAGGGACC-3′), MMP-9 (forward: 5′-CACTGTAACTGGGGGCGACT-3′; reverse: 5′-GCATTGCTACTGCTGCGATAA-3′), TIMP-1 (forward: 5′-CATCTCTTGCTGCGTAAGTCA-3′; reverse: 5′-GGGAATGTTTTGAGAACATGGAGA-3′), β-actin (forward: 5′-CAGACGAGACTGGCATGTTGCA-3′; reverse: 5′-CCCATGTTAAGTTCGATGCTG-3′), PCR was performed 95 °C for 10 minutes followed by 40 cycles at 95 °C for 15 seconds and at 60 °C about 1 minute by using Thermo Step One. Reactions were conducted three times, and threshold cycle values were normalized to β-actin gene expression. The specificity of the products was determined by melting curve analysis. Relative mRNA expression of target genes were normalized to control group and the level of β-actin.

**Western blot.** Cultured FLSs were lysed with lysis buffer for Western (Beyotime, China). The whole-cell extracts (20 mg of protein) were then fractionated by electrophoresis through a 10–12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto PVDF membranes (Millipore, USA). After blockade of nonspecific protein binding, nitrocellulose blots were incubated for more 12 h with primary
antibodies diluted in primary antibody Dilution Buffer (Beyotime, China). Rabbit antibodies β-catenin, C-myc and CyclinD1 were used at 1:500 and β-actin was used at 1:1000. After incubation with primary antibodies, blots were washed four times in TBS/Tween-20 before incubation for 1 h in goat anti-mouse or anti-rabbit horseradish peroxidase conjugate antibody at 1:10000 dilutions in TBS/Tween-20 containing 5% skim milk. After washing four times with TBS/Tween-20 the protein blots were detected using the ECL-chemiluminescent kit (ECL-plus, Thermo Scientific, USA).

**Statistical analysis.** Data are presented as means ± SD and were analyzed using SPSS16.0 software. Statistical significances were determined by one-way ANOVA with the post-hoc Dunnett’s test. In all cases, values of P < 0.05 were considered to be statistically significant.

**References**

1. Feldmann, M., Brennan, F. M. & Maini, R. N. Rheumatoid arthritis. Cell 85, 307–310 (1996).
2. Elshabrawy, H. A. et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis (2015).
3. Dulos, J. et al. p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes. Clin Exp Rheumatol 31, 515–525 (2013).
4. Yeremenko, N. et al. Brief Report: Tumor Necrosis Factor and Interleukin-6 Differentially Regulate Dkk-1 in the Inflamed Arthritic Joint. Arthritis Rheumatol 67, 2071–2075 (2015).
5. Koga, T. et al. Post-transcriptional regulation of IL-6 production by Zc3h12a in fibroblast-like synovial cells. Clin Exp Rheumatol 29, 906–911 (2011).
6. Kontny, E., Janicka, I., Skalska, U. & Maslinski, W. The effect of multimeric adiponectin isoforms and leptin on the function of rheumatoid fibroblast-like synoviocytes. Scand J Rheumatol 1–6 (2015).
7. Fava, R. A. et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180, 341–346 (1994).
8. Pap, T. et al. Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis. Arthritis Rheum 43, 2531–2536 (2000).
9. Zhu, J. et al. Overexpression of Supraspinus is Associated with Proliferation and Tumorigenicity of Esophageal Squamous Cell Carcinoma. Sci Rep 6, 21549 (2016).
10. Martin, G. et al. Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients. Sci Rep 4, 5002 (2014).
11. Ormseth, M. J. et al. Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor gamma agonist therapy. Arthritis Rheumatol 66, 2331–2338 (2014).
12. Lee, Y. H., Bae, S. C. & Song, G. G. Meta-analysis of associations between the peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis. Genet Test Mol Biomarkers 18, 341–348 (2014).
13. Moore-Carrasco, R. et al. Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review). Mol Med Rep 1, 317–324 (2008).
14. Roberts-Thomson, S. J. Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment. Immunol Cell Biol 78, 436–441 (2000).
15. Abbas, A., Blandon, J., Rude, J., Elfar, A. & Mukherjee, D. PPAR-gamma agonist in treatment of diabetes: cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem 10, 124–134 (2012).
16. Feng, X. et al. Chrysines attenuates inflammation by regulating M1/M2 status via activating PPARgamma. Biochem Pharmacol 89, 503–514 (2014).
17. Koulany, M. et al. The peroxisome proliferator-activated receptor gamma agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. Arthritis Rheum 65, 3084–3095 (2013).
18. Mader, W. et al. The peroxisome proliferator-activated receptor-gamma pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J Am Heart Assoc 2, e00441 (2013).
19. Rabelo Fde, S. et al. The Wnt signaling pathway and rheumatoid arthritis. Autoimmun Rev 9, 207–210 (2010).
20. Imai, K. et al. Differential expression of WNTs and FRPs in the synovium of rheumatoid arthritis and osteoarthritis. Biochem Biophys Res Commun 345, 1615–1620 (2006).
21. Logan, C. Y. & Nüsse, R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20, 781–810 (2004).
22. Moon, R. T., Brown, J. D. & Torres, M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 13, 157–162 (1997).
23. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
24. Schneider, S. et al. The prognostic significance of beta-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: beta-catenin predicts overall survival. Eur Arch Otorhinolaryngol 2015.
25. Li, X., Wang, X., Wang, Y., Huang, C. & Li, J. Inhibition of transient receptor potential melastatin 7 (TRPM7) channel induces RA FLSs apoptosis through endoplasmic reticulum (ER) stress. Clin Rheumatol 33, 1565–1574 (2014).
26. Li, X. F. et al. MicroRNA-20a negatively regulates expression of NLRP3-inflammasome by targeting TXNIP in adjuvant-induced arthritis fibroblast-like synoviocytes. Joint Bone Spine 83, 21549 (2016).
27. Smeets, T. J. et al. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthritic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 62, 635–638 (2003).
28. Larsen, H., Muz, B., Khong, T. L., Feldmann, M. & Paleolog, E. M. Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA. Arthritis Res Ther 14, R180 (2012).
29. Lee, D. G., Woo, J. W., Kook, S. K., Cho, M. I. & Park, S. H. MRF8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Exp Mol Med 45, e20 (2013).
30. Park, S. I., Kim, K. J., Kim, W. U. & Cho, C. S. Interaction of mesenchymal stem cells with fibroblast-like synoviocytes via cadherin-11 promotes angiogenesis by enhanced secretion of placental growth factor. J Immunol 192, 3003–3010 (2014).
31. Huh, Y. H. et al. HIF-2alpha-induced chemokines stimulate motility of fibroblast-like synoviocytes and chondrocytes into the cartilage-pannus interface in experimental rheumatoid arthritis mouse models. Arthritis Res Ther 17, 302 (2015).
32. Sahbekkar, A., Chaw, G. T. & Watts, G. F. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 15, 493–503 (2014).
33. Zhang, J. G. et al. MIR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/beta-catenin pathway. Sci Rep 5, 8087 (2015).
34. Bae, S. Y., Kim, H. J., Lee, K. J. & Lee, K. Transiently controlled tumor protein induces epithelial to mesenchymal transition and promotes cell migration, invasion and metastasis. Sci Rep 5, 8061 (2015).
35. Bao, X. et al. The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages. *J Mol Med (Berl)* **85**, 85–98 (2007).
36. Gu, J., Hu, W. & Liu, X. Pioglitazone improves potassium channel remodeling induced by angiotensin II in atrial myocytes. *Med Sci Monit Basic Res* **20**, 153–160 (2014).
37. Saha, L., Bhandari, S., Bhatia, A., Banerjee, D. & Chakrabarti, A. Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model. *J Epilepsy Res* **4**, 45–54 (2014).
38. Laghezza, A. et al. On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles. *ChemMedChem* **10**, 555–565 (2015).

**Acknowledgements**

This study is supported by the National Science Fundations of China (NO. 81473268, 81273526, 81202978, 81500473), Specialized Research Fund for the Doctoral Program of Higher Education (20123420120001), Anhui Provincial Natural Science Foundation (1308085MH145, KJ2012Z169).

**Author Contributions**

X.F. Li performed all experiments, analyzed the data and wrote the manuscript. J. Bao helped to collect the RA, OA and normal synovial tissues. Y.Y. Sun, X. Chen and Y.H. Li helped to isolated FLSs and helped to Western blot, Q-PCR and histological analysis. L. Zhang, C. Huang and B.M. Wu participated in the design of the study. X.M. Meng helped to revise the manuscript. J. Li conceived the study and revised the manuscript. All authors approved the final manuscript.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017